

# Shitij Kapur

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3463824/shitij-kapur-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

303  
papers

33,154  
citations

93  
h-index

175  
g-index

319  
ext. papers

36,720  
ext. citations

5.8  
avg. IF

7.39  
L-index

#	Paper	IF	Citations
303	Adenosine A receptor in schizophrenia: an in vivo brain PET imaging study. <i>Psychopharmacology</i> , <b>2021</b> , 1	4.7	1
302	Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA). <i>Schizophrenia Bulletin</i> , <b>2021</b> , 47, 505-516	1.3	14
301	The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study. <i>Biological Psychiatry</i> , <b>2019</b> , 85, 79-87	7.9	36
300	Determinants of treatment response in first-episode psychosis: an F-DOPA PET study. <i>Molecular Psychiatry</i> , <b>2019</b> , 24, 1502-1512	15.1	78
299	Moment-to-moment associations between negative affect, aberrant salience, and paranoia. <i>Cognitive Neuropsychiatry</i> , <b>2018</b> , 23, 299-306	2	15
298	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. <i>Lancet Psychiatry</i> , <b>2018</b> , 5, 797-807	23.3	100
297	Pharmacogenetics of antidepressant response: A polygenic approach. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2017</b> , 75, 128-134	5.5	54
296	Connectomic correlates of response to treatment in first-episode psychosis. <i>Brain</i> , <b>2017</b> , 140, 487-496	11.2	36
295	The effect of perinatal brain injury on dopaminergic function and hippocampal volume in adult life. <i>ELife</i> , <b>2017</b> , 6,	8.9	21
294	The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching Antipsychotics. <i>Focus (American Psychiatric Publishing)</i> , <b>2016</b> , 14, 378-386	1.1	1
293	Translating genome-wide association findings into new therapeutics for psychiatry. <i>Nature Neuroscience</i> , <b>2016</b> , 19, 1392-1396	25.5	86
292	Initial depression severity and response to antidepressants v. placebo: patient-level data analysis from 34 randomised controlled trials. <i>British Journal of Psychiatry</i> , <b>2016</b> , 209, 427-428	5.4	42
291	Phosphodiesterase 10A in Schizophrenia: A PET Study Using [(11)C]IMA107. <i>American Journal of Psychiatry</i> , <b>2016</b> , 173, 714-21	11.9	26
290	Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial. <i>Journal of Clinical Psychiatry</i> , <b>2016</b> , 77, 1381-1390	4.6	9
289	Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. <i>Lancet Psychiatry</i> , <b>2016</b> , 3, 1115-1128	23.3	45
288	Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. <i>Journal of the Neurological Sciences</i> , <b>2016</b> , 368, 243-8	3.2	32
287	Biomarkers of treatment outcome in schizophrenia: Defining a benchmark for clinical significance. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 1578-85	1.2	4

286	Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. <i>Brain</i> , <b>2015</b> , 138, 3003-15	11.2	74
285	Changes in delusional dimensions and emotions over eight weeks of antipsychotic treatment in acute patients. <i>Psychiatry Research</i> , <b>2015</b> , 228, 393-8	9.9	4
284	Modafinil combined with cognitive training: pharmacological augmentation of cognitive training in schizophrenia. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 1178-89	1.2	35
283	Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank. <i>International Journal of Neuropsychopharmacology</i> , <b>2015</b> , 18, pyv042	5.8	71
282	The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 549-58	1.3	38
281	The promise of biological markers for treatment response in first-episode psychosis: a systematic review. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 559-73	1.3	65
280	Calibration and cross-validation of MCCB and CogState in schizophrenia. <i>Psychopharmacology</i> , <b>2015</b> , 232, 3873-82	4.7	27
279	Effects of haloperidol and aripiprazole on the human mesolimbic motivational system: A pharmacological fMRI study. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 2252-61	1.2	6
278	Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 2098-107	1.2	55
277	NEWMEDS special issue commentary. <i>Psychopharmacology</i> , <b>2015</b> , 232, 3849-51	4.7	4
276	Predicting clinical response in people at ultra-high risk of psychosis: a systematic and quantitative review. <i>Drug Discovery Today</i> , <b>2015</b> , 20, 924-7	8.8	8
275	Longitudinal in vivo maturational changes of metabolites in the prefrontal cortex of rats exposed to polyinosinic-polycytidylic acid in utero. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 2210-20	1.2	23
274	Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. <i>Brain</i> , <b>2015</b> , 138, 3016-29	11.2	71
273	Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 212-23	4.6	19
272	The effects of a single dose of oxytocin on working memory in schizophrenia. <i>Schizophrenia Research</i> , <b>2015</b> , 162, 62-3	3.6	21
271	UK Doubles Its "World-Leading" Research in Life Sciences and Medicine in Six Years: Testing the Claim?. <i>PLoS ONE</i> , <b>2015</b> , 10, e0132990	3.7	10
270	Mobile early detection and connected intervention to coproduce better care in severe mental illness. <i>Studies in Health Technology and Informatics</i> , <b>2015</b> , 216, 123-6	0.5	6
269	CNVs conferring risk of autism or schizophrenia affect cognition in controls. <i>Nature</i> , <b>2014</b> , 505, 361-6	50.4	444

268	Phosphodiesterase 10A PET radioligand development program: from pig to human. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 595-601	8.9	46
267	Combining efficacy and completion rates with no data imputation: a composite approach with greater sensitivity for the statistical evaluation of active comparisons in antipsychotic trials. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, 357-68	1.2	2
266	Changes in delusions in the early phase of antipsychotic treatment - an experience sampling study. <i>Psychiatry Research</i> , <b>2014</b> , 215, 568-73	9.9	34
265	Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. <i>Biological Psychiatry</i> , <b>2014</b> , 75, e11-3	7.9	218
264	Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs-linking magnetic resonance imaging findings to cellular pathology. <i>Biological Psychiatry</i> , <b>2014</b> , 75, 982-90	7.9	69
263	Clinically meaningful biomarkers for psychosis: a systematic and quantitative review. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2014</b> , 45, 134-41	9	67
262	White matter integrity as a predictor of response to treatment in first episode psychosis. <i>Brain</i> , <b>2014</b> , 137, 172-82	11.2	114
261	Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. <i>British Journal of Psychiatry</i> , <b>2014</b> , 204, 420-9	5.4	86
260	How antipsychotics impact the different dimensions of Schizophrenia: a test of competing hypotheses. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, 1279-88	1.2	10
259	Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. <i>Biological Psychiatry</i> , <b>2014</b> , 75, 470-8	7.9	143
258	The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study. <i>Psychopharmacology</i> , <b>2014</b> , 231, 2251-9	4.7	72
257	The Enduring Centrality of Dopamine in the Pathophysiology of Schizophrenia: In Vivo Evidence from the Prodrome to the First Psychotic Episode <b>2014</b> , 151-152		
256	Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain. <i>Human Brain Mapping</i> , <b>2013</b> , 34, 272-82	5.9	78
255	The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory : A dual [(11)C]raclopride and [(18) F]FDG imaging study with aripiprazole. <i>Psychopharmacology</i> , <b>2013</b> , 227, 221-9	4.7	38
254	Integrating mobile-phone based assessment for psychosis into people's everyday lives and clinical care: a qualitative study. <i>BMC Psychiatry</i> , <b>2013</b> , 13, 34	4.2	99
253	Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. <i>Schizophrenia Research</i> , <b>2013</b> , 150, 328-33	3.6	38
252	Detecting improvements in acute psychotic symptoms using experience sampling methodology. <i>Psychiatry Research</i> , <b>2013</b> , 210, 82-8	9.9	25
251	Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 19-27	4.6	287

250	Treating impaired cognition in schizophrenia: the case for combining cognitive-enhancing drugs with cognitive remediation. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, 790-8	1.2	22
249	Negative symptoms in schizophrenia--the remarkable impact of inclusion definitions in clinical trials and their consequences. <i>Schizophrenia Research</i> , <b>2013</b> , 150, 334-8	3.6	40
248	Establishing test-retest reliability of an adapted [(18)F]fallypride imaging protocol in older people. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2013</b> , 33, 1098-103	7.3	16
247	Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. <i>American Journal of Psychiatry</i> , <b>2013</b> , 170, 1335-44	11.9	95
246	Microvascular abnormality in schizophrenia as shown by retinal imaging. <i>American Journal of Psychiatry</i> , <b>2013</b> , 170, 1451-9	11.9	72
245	Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. <i>Journal of Clinical Psychopharmacology</i> , <b>2013</b> , 33, 329-35	1.7	35
244	A comparison of two delivery modalities of a mobile phone-based assessment for serious mental illness: native smartphone application vs text-messaging only implementations. <i>Journal of Medical Internet Research</i> , <b>2013</b> , 15, e60	7.6	95
243	Molecular imaging as a guide for the treatment of central nervous system disorders. <i>Dialogues in Clinical Neuroscience</i> , <b>2013</b> , 15, 315-28	5.7	13
242	Aminergic Hypothesis for Schizophrenia <b>2013</b> , 1-6		
241	Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2012</b> , 32, 759-68	7.3	24
240	Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. <i>American Journal of Psychiatry</i> , <b>2012</b> , 169, 1203-10	11.9	230
239	The nature of dopamine dysfunction in schizophrenia and what this means for treatment. <i>Archives of General Psychiatry</i> , <b>2012</b> , 69, 776-86		616
238	Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. <i>Archives of General Psychiatry</i> , <b>2012</b> , 69, 1195-204		110
237	Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. <i>Biological Psychiatry</i> , <b>2012</b> , 71, 855-63	7.9	101
236	Alterations of the brain reward system in antipsychotic naïve schizophrenia patients. <i>Biological Psychiatry</i> , <b>2012</b> , 71, 898-905	7.9	157
235	Reply to: Lithium and the Expanding Brain. <i>Biological Psychiatry</i> , <b>2012</b> , 72, e19	7.9	
234	Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. <i>Schizophrenia Research</i> , <b>2012</b> , 137, 147-50	3.6	234
233	Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?. <i>Molecular Psychiatry</i> , <b>2012</b> , 17, 1174-9	15.1	685

232	Role of dopamine D(2) receptors for antipsychotic activity. <i>Handbook of Experimental Pharmacology</i> , <b>2012</b> , 27-52	3.2	90
231	The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. <i>BMC Psychiatry</i> , <b>2012</b> , 12, 172	4.2	118
230	Jumping to conclusions, a lack of belief flexibility and delusional conviction in psychosis: a longitudinal investigation of the structure, frequency, and relatedness of reasoning biases. <i>Journal of Abnormal Psychology</i> , <b>2012</b> , 121, 129-139	7	108
229	Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. <i>PLoS Medicine</i> , <b>2012</b> , 9, e1001326	11.6	94
228	Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial. <i>Journal of Clinical Psychopharmacology</i> , <b>2012</b> , 32, 95-9	1.7	15
227	Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. <i>British Journal of Psychiatry</i> , <b>2012</b> , 201, 481-5	5.4	220
226	Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. <i>Biological Psychiatry</i> , <b>2011</b> , 69, 936-44	7.9	139
225	Exploring the neural correlates of delusions of reference. <i>Biological Psychiatry</i> , <b>2011</b> , 70, 1127-33	7.9	49
224	Ventajas y desventajas del tratamiento de combinaci3n con antipsic3ticos. Reuni3n ECNP Consensus, marzo de 2008, Niza. <i>Psiquiatria Biologica</i> , <b>2011</b> , 18, 55-67	0.2	2
223	What Kraepelin might say about schizophrenia: just the facts. <i>Schizophrenia Research</i> , <b>2011</b> , 128, 1-2	3.6	3
222	Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. <i>Schizophrenia Research</i> , <b>2011</b> , 130, 11-9	3.6	29
221	Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. <i>Schizophrenia Research</i> , <b>2011</b> , 131, 63-8	3.6	72
220	The evolution of antipsychotic switch and polypharmacy in natural practice--a longitudinal perspective. <i>Schizophrenia Research</i> , <b>2011</b> , 130, 40-6	3.6	47
219	Haloperidol modulates noradrenergic responses to aversive stimulation depending on treatment duration. <i>Behavioural Brain Research</i> , <b>2011</b> , 221, 311-3	3.4	10
218	Disruption of frontal coherence by $\Delta^9$ -tetrahydrocannabinol is associated with positive psychotic symptoms. <i>Neuropsychopharmacology</i> , <b>2011</b> , 36, 827-36	8.7	68
217	Grand challenges in global mental health. <i>Nature</i> , <b>2011</b> , 475, 27-30	50.4	1310
216	Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 1108-23	4.6	29
215	Aberrant Effective Connectivity in Schizophrenia Patients during Appetitive Conditioning. <i>Frontiers in Human Neuroscience</i> , <b>2011</b> , 4, 239	3.3	34

214	Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment. <i>International Journal of Neuropsychopharmacology</i> , <b>2011</b> , 14, 1327-39	5.8	39
213	Calculating occupancy when one does not have baseline: a comparison of different options. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2011</b> , 31, 1760-7	7.3	7
212	The use of healthy volunteers instead of patients to inform drug dosing studies: a [ <sup>11</sup> C]raclopride PET study. <i>Psychopharmacology</i> , <b>2011</b> , 217, 515-23	4.7	11
211	Effects of aging on 5-HT(2A) R binding: a HRRT PET study with and without partial volume corrections. <i>International Journal of Geriatric Psychiatry</i> , <b>2011</b> , 26, 1300-8	3.9	23
210	Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies. <i>Human Psychopharmacology</i> , <b>2011</b> , 26, 282-90	2.3	9
209	Looking for a "biological test" to diagnose "schizophrenia": are we chasing red herrings?. <i>World Psychiatry</i> , <b>2011</b> , 10, 32	14.4	11
208	Does intravenous $\Delta$ -tetrahydrocannabinol increase dopamine release? A SPET study. <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 1462-8	4.6	77
207	Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models. <i>International Journal of Neuropsychopharmacology</i> , <b>2011</b> , 14, 1165-78	5.8	23
206	How change comes: translating biological research into care. <i>The Psychiatrist</i> , <b>2011</b> , 35, 321-324		1
205	An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 1439-44	4.6	146
204	"Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 1042-8	4.6	47
203	Is desire for social relationships mediated by the serotonergic system in the prefrontal cortex? An [(18)F]setoperone PET study. <i>Social Neuroscience</i> , <b>2010</b> , 5, 375-83	2	23
202	Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. <i>Neuropsychopharmacology</i> , <b>2010</b> , 35, 581-90	8.7	145
201	The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro. <i>Neuropsychopharmacology</i> , <b>2010</b> , 35, 1826-35	8.7	55
200	Blockade of [ <sup>11</sup> C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. <i>International Journal of Neuropsychopharmacology</i> , <b>2010</b> , 13, 273-87	5.8	58
199	Specific and generalized neuropsychological deficits: a comparison of patients with various first-episode psychosis presentations. <i>American Journal of Psychiatry</i> , <b>2010</b> , 167, 78-85	11.9	152
198	Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia. <i>Schizophrenia Research</i> , <b>2010</b> , 118, 176-82	3.6	19
197	Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization. <i>Molecular Brain</i> , <b>2010</b> , 3, 25	4.5	67

196	Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. <i>Neuropsychopharmacology</i> , <b>2010</b> , 35, 764-74	8.7	481
195	Early onset of antipsychotic action in schizophrenia: evaluating the possibility of shorter acute efficacy trials. <i>Journal of Clinical Psychopharmacology</i> , <b>2010</b> , 30, 286-9	1.7	10
194	Do antipsychotics improve reasoning biases? A review. <i>Psychosomatic Medicine</i> , <b>2010</b> , 72, 681-93	3.7	53
193	Antipsychotic dosing: how much but also how often?. <i>Schizophrenia Bulletin</i> , <b>2010</b> , 36, 900-3	1.3	50
192	Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission. <i>Journal of Psychiatric Research</i> , <b>2010</b> , 44, 8-14	5.2	23
191	The effects of reality distortion syndrome on salient stimuli processing in patients with schizophrenia: an fMRI study. <i>Psychiatry Research - Neuroimaging</i> , <b>2010</b> , 183, 93-8	2.9	5
190	The neurobiology of schizophrenia: new leads and avenues for treatment. <i>Current Opinion in Neurobiology</i> , <b>2010</b> , 20, 810-5	7.6	20
189	Dopamine-induced changes in neural network patterns supporting aversive conditioning. <i>Brain Research</i> , <b>2010</b> , 1313, 143-61	3.7	25
188	A systematic review of aripiprazole--dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, 1447-56	4.6	75
187	Dopamine Receptors and the Treatment of Schizophrenia <b>2010</b> , 431-477		5
186	The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. <i>Psychological Medicine</i> , <b>2009</b> , 39, 1607-16	6.9	226
185	The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO. <i>Archives of General Psychiatry</i> , <b>2009</b> , 66, 606-15		88
184	Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. <i>Brain</i> , <b>2009</b> , 132, 1366-75	11.2	85
183	The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. <i>International Journal of Neuropsychopharmacology</i> , <b>2009</b> , 12, 715-21	5.8	41
182	D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. <i>Neuropsychopharmacology</i> , <b>2009</b> , 34, 662-71	8.7	67
181	The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. <i>Neuropsychopharmacology</i> , <b>2009</b> , 34, 1078-86	8.7	93
180	Gestational treatment with methylazoxymethanol (MAM) that disrupts hippocampal-dependent memory does not alter behavioural response to cocaine. <i>Pharmacology Biochemistry and Behavior</i> , <b>2009</b> , 93, 382-90	3.9	12
179	Dopaminergic activity in depressed smokers: a positron emission tomography study. <i>Synapse</i> , <b>2009</b> , 63, 681-9	2.4	41



178	Ex vivo [ <sup>11</sup> C](+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D2 receptor in vitro. <i>Synapse</i> , <b>2009</b> , 63, 998-1009	2.4	22
177	The dopamine hypothesis of schizophrenia: version III--the final common pathway. <i>Schizophrenia Bulletin</i> , <b>2009</b> , 35, 549-62	1.3	1721
176	Effects of the dopamine stabilizer, OSU-6162, on brain stimulation reward and on quinpirole-induced changes in reward and locomotion. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, 416-30	1.2	20
175	Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, 520-32	1.2	101
174	BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, 841-50	1.2	9
173	Schizophrenia. <i>Lancet, The</i> , <b>2009</b> , 374, 635-45	4.0	1558
172	Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. <i>American Journal of Geriatric Psychiatry</i> , <b>2009</b> , 17, 255-63	6.5	50
171	D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , <b>2009</b> , 29, 571-5	1.7	38
170	Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 2550-9	3.3	181
169	Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. <i>Journal of Clinical Psychiatry</i> , <b>2009</b> , 70, 397-405	4.6	81
168	Clozapine and olanzapine exhibit an intrinsic anxiolytic property in two conditioned fear paradigms: contrast with haloperidol and chlordiazepoxide. <i>Pharmacology Biochemistry and Behavior</i> , <b>2008</b> , 90, 551-62	3.9	43
167	New and old antipsychotics: what effectiveness trials tell us. <i>Psychiatry (Abingdon, England)</i> , <b>2008</b> , 7, 443-446		1
166	'Jumping to conclusions' and delusions in psychosis: relationship and response to treatment. <i>Schizophrenia Research</i> , <b>2008</b> , 98, 225-31	3.6	90
165	Attribution style as a factor in psychosis and symptom resolution. <i>Schizophrenia Research</i> , <b>2008</b> , 104, 220-7	3.6	26
164	Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. <i>Biological Psychiatry</i> , <b>2008</b> , 64, 145-52	7.9	82
163	Dopamine D2 receptor radiotracers [ <sup>11</sup> C](+)-PHNO and [ <sup>3</sup> H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo. <i>Nuclear Medicine and Biology</i> , <b>2008</b> , 35, 11-7	2.1	44
162	A sensitizing regimen of amphetamine that disrupts attentional set-shifting does not disrupt working or long-term memory. <i>Behavioural Brain Research</i> , <b>2008</b> , 189, 170-9	3.4	52
161	Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine. <i>Schizophrenia Research</i> , <b>2008</b> , 105, 224-35	3.6	57

160	Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. <i>Schizophrenia Research</i> , <b>2008</b> , 102, 241-8	3.6	36
159	Emerging drugs for schizophrenia. <i>Expert Opinion on Emerging Drugs</i> , <b>2008</b> , 13, 479-95	3.7	38
158	Variations of rest activity rhythm and sleep wake in schizophrenic patients versus healthy subjects: An actigraphic comparative study. <i>Biological Rhythm Research</i> , <b>2008</b> , 39, 69-78	0.8	14
157	The formation of abnormal associations in schizophrenia: neural and behavioral evidence. <i>Neuropsychopharmacology</i> , <b>2008</b> , 33, 473-9	8.7	168
156	First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: A [11C]-(+)-PHNO positron emission tomography study. <i>Neuropsychopharmacology</i> , <b>2008</b> , 33, 279-89	8.7	101
155	D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. <i>Neuropsychopharmacology</i> , <b>2008</b> , 33, 298-304	8.7	58
154	The antipsychotic potential of l-stepholidine--a naturally occurring dopamine receptor D1 agonist and D2 antagonist. <i>Psychopharmacology</i> , <b>2008</b> , 199, 275-89	4.7	46
153	Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. <i>Human Brain Mapping</i> , <b>2008</b> , 29, 400-10	5.9	86
152	Pharmacogenetics in psychiatry: are we ready for widespread clinical use?. <i>Schizophrenia Bulletin</i> , <b>2008</b> , 34, 1130-44	1.3	85
151	Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 81-6	4.6	34
150	Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 1281-6	4.6	36
149	A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease. <i>American Journal of Geriatric Psychiatry</i> , <b>2007</b> , 15, 888-98	6.5	33
148	Temporal difference modeling of the blood-oxygen level dependent response during aversive conditioning in humans: effects of dopaminergic modulation. <i>Biological Psychiatry</i> , <b>2007</b> , 62, 765-72	7.9	126
147	Separate brain regions code for salience vs. valence during reward prediction in humans. <i>Human Brain Mapping</i> , <b>2007</b> , 28, 294-302	5.9	143
146	Quantification of l-stepholidine in rat brain and plasma by high performance liquid chromatography combined with fluorescence detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2007</b> , 850, 544-7	3.2	3
145	Increased dopamine D2(High) receptors in amphetamine-sensitized rats, measured by the agonist [(3)H](+)PHNO. <i>Synapse</i> , <b>2007</b> , 61, 263-7	2.4	46
144	Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2007</b> , 27, 857-71	7.3	83
143	Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. <i>American Journal of Psychiatry</i> , <b>2007</b> , 164, 630-7	11.9	126

142	"Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. <i>Journal of Neuroscience</i> , <b>2007</b> , 27, 2979-86	6.6	200
141	Linking animal models of psychosis to computational models of dopamine function. <i>Neuropsychopharmacology</i> , <b>2007</b> , 32, 54-66	8.7	30
140	Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward. <i>Neuropsychopharmacology</i> , <b>2007</b> , 32, 551-61	8.7	36
139	Time course of the antipsychotic effect and the underlying behavioral mechanisms. <i>Neuropsychopharmacology</i> , <b>2007</b> , 32, 263-72	8.7	61
138	A sensitizing regimen of amphetamine impairs visual attention in the 5-choice serial reaction time test: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. <i>Neuropsychopharmacology</i> , <b>2007</b> , 32, 1122-32	8.7	67
137	Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies. <i>Neuropsychopharmacology</i> , <b>2007</b> , 32, 1540-9	8.7	40
136	Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. <i>American Journal of Psychiatry</i> , <b>2007</b> , 164, 1411-7	11.9	205
135	Gestational methylazoxymethanol acetate treatment impairs select cognitive functions: parallels to schizophrenia. <i>Neuropsychopharmacology</i> , <b>2007</b> , 32, 483-92	8.7	96
134	Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia. <i>Neuropsychopharmacology</i> , <b>2007</b> , 32, 1209-15	8.7	106
133	The effect of antipsychotic treatment on Theory of Mind. <i>Psychological Medicine</i> , <b>2007</b> , 37, 595-601	6.9	48
132	Early use of clozapine for poorly responding first-episode psychosis. <i>Journal of Clinical Psychopharmacology</i> , <b>2007</b> , 27, 369-73	1.7	66
131	Amoxapine as an antipsychotic: comparative study versus haloperidol. <i>Journal of Clinical Psychopharmacology</i> , <b>2007</b> , 27, 575-81	1.7	16
130	The amphetamine-induced sensitized state as a model of schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2007</b> , 31, 1556-71	5.5	151
129	How antipsychotics work--from receptors to reality. <i>NeuroRx</i> , <b>2006</b> , 3, 10-21		68
128	An automated method for the extraction of regional data from PET images. <i>Psychiatry Research - Neuroimaging</i> , <b>2006</b> , 147, 79-89	2.9	129
127	A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 396-401	11.9	116
126	Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. <i>Neuropsychopharmacology</i> , <b>2006</b> , 31, 1854-63	8.7	177
125	The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2006</b> , 318, 810-8	4.7	68

124	Dopamine, prediction error and associative learning: a model-based account. <i>Network: Computation in Neural Systems</i> , <b>2006</b> , 17, 61-84	0.7	56
123	High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO. <i>Biological Psychiatry</i> , <b>2006</b> , 59, 389-94	7.9	122
122	A model of anticholinergic activity of atypical antipsychotic medications. <i>Schizophrenia Research</i> , <b>2006</b> , 88, 63-72	3.6	105
121	The selective effect of antipsychotics on the different dimensions of the experience of psychosis in schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , <b>2006</b> , 88, 111-8	3.6	46
120	In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system. <i>Synapse</i> , <b>2006</b> , 60, 172-83	2.4	22
119	Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus. <i>Synapse</i> , <b>2006</b> , 60, 205-11	2.4	61
118	Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. <i>Journal of Neurochemistry</i> , <b>2006</b> , 97, 1089-103	6	134
117	The "delayed onset" of antipsychotic action--an idea whose time has come and gone. <i>Journal of Psychiatry and Neuroscience</i> , <b>2006</b> , 31, 93-100	4.5	77
116	Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. <i>Journal of Medicinal Chemistry</i> , <b>2005</b> , 48, 4153-60	8.3	207
115	How antipsychotics work: the patients' perspective. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2005</b> , 29, 859-64	5.5	28
114	Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. <i>Biological Psychiatry</i> , <b>2005</b> , 57, 406-11	7.9	36
113	A putative animal model of the "prodromal" state of schizophrenia. <i>Biological Psychiatry</i> , <b>2005</b> , 57, 586-93	7.9	57
112	Effects of chronic typical and atypical antipsychotic drug treatment on maternal behavior in rats. <i>Schizophrenia Research</i> , <b>2005</b> , 75, 325-36	3.6	29
111	From dopamine to salience to psychosis--linking biology, pharmacology and phenomenology of psychosis. <i>Schizophrenia Research</i> , <b>2005</b> , 79, 59-68	3.6	367
110	Contrasting loxapine to its isomer isloxapine--the critical role of in vivo D2 blockade in determining atypicality. <i>Schizophrenia Research</i> , <b>2005</b> , 77, 189-99	3.6	9
109	"Extended" antipsychotic dosing: rationale and pilot data. <i>Journal of Clinical Psychopharmacology</i> , <b>2005</b> , 25, 611-3	1.7	24
108	Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis. <i>Canadian Journal of Psychiatry</i> , <b>2005</b> , 50, 462-9	4.8	21
107	Effects of novel antipsychotics, amisulpiride and aripiprazole, on maternal behavior in rats. <i>Psychopharmacology</i> , <b>2005</b> , 181, 600-10	4.7	22

106	Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. <i>Psychopharmacology</i> , <b>2005</b> , 183, 190-200	4.7	108
105	Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition. <i>Psychopharmacology</i> , <b>2005</b> , 180, 366-76	4.7	69
104	Amoxapine as an atypical antipsychotic: a comparative study vs risperidone. <i>Neuropsychopharmacology</i> , <b>2005</b> , 30, 2236-44	8.7	25
103	Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 5815-23	6.6	171
102	A computational model of the functional role of the ventral-striatal D2 receptor in the expression of previously acquired behaviors. <i>Neural Computation</i> , <b>2005</b> , 17, 361-95	2.9	28
101	Evidence for onset of antipsychotic effects within the first 24 hours of treatment. <i>American Journal of Psychiatry</i> , <b>2005</b> , 162, 939-46	11.9	154
100	PET imaging of DA neurotransmission using agonist versus antagonist radiotracers. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2005</b> , 25, S715-S715	7.3	
99	The D2-agonist radiotracer [11C]-(+)-PHNO shows a marked increase in sensitivity to amphetamine challenges when compared to [11C]raclopride in the cat brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2005</b> , 25, S611-S611	7.3	
98	Evaluation of [11C]-(+)-PHNO as an agonist radiotracer for imaging high-affinity dopamine D2 receptors. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2005</b> , 25, S594-S594	7.3	
97	A model of antipsychotic action in conditioned avoidance: a computational approach. <i>Neuropsychopharmacology</i> , <b>2004</b> , 29, 1040-9	8.7	25
96	Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. <i>American Journal of Psychiatry</i> , <b>2004</b> , 161, 1620-5	11.9	118
95	Relation between cortical dopamine D(2) receptor occupancy and suppression of conditioned avoidance response in non-human primate. <i>Psychiatry and Clinical Neurosciences</i> , <b>2004</b> , 58, 330-2	6.2	4
94	Evaluation of the motor initiation hypothesis of APD-induced conditioned avoidance decreases. <i>Pharmacology Biochemistry and Behavior</i> , <b>2004</b> , 78, 811-9	3.9	40
93	EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study. <i>Psychopharmacology</i> , <b>2004</b> , 175, 382-8	4.7	14
92	Oral D-amphetamine causes prolonged displacement of [11C]raclopride as measured by PET. <i>Synapse</i> , <b>2004</b> , 51, 27-31	2.4	51
91	Quantitative validation of an intracerebral beta-sensitive microprobe system to determine in vivo drug-induced receptor occupancy using [11C]raclopride in rats. <i>Synapse</i> , <b>2004</b> , 52, 89-99	2.4	24
90	Effect of acute antipsychotic administration on dopamine synthesis in rodents and human subjects using 6-[18F]-L-m-tyrosine. <i>Synapse</i> , <b>2004</b> , 52, 153-62	2.4	10
89	Amphetamine pretreatment induces a change in both D2-Receptor density and apparent affinity: a [11C]raclopride positron emission tomography study in cats. <i>Biological Psychiatry</i> , <b>2004</b> , 55, 1188-94	7.9	40

88	Effects of typical and atypical antipsychotic drugs on maternal behavior in postpartum female rats. <i>Schizophrenia Research</i> , <b>2004</b> , 70, 69-80	3.6	48
87	How antipsychotics become anti-"psychotic"--from dopamine to salience to psychosis. <i>Trends in Pharmacological Sciences</i> , <b>2004</b> , 25, 402-6	13.2	95
86	Amoxapine in schizophrenia: a negative double-blind controlled trial. <i>Journal of Clinical Psychopharmacology</i> , <b>2004</b> , 24, 448-50	1.7	5
85	A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. <i>American Journal of Psychiatry</i> , <b>2004</b> , 161, 818-25	11.9	167
84	The newer antipsychotics: underlying mechanisms and the new clinical realities. <i>Current Opinion in Psychiatry</i> , <b>2004</b> , 17, 115-121	4.9	9
83	Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2003</b> , 305, 625-31	4.7	398
82	Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. <i>American Journal of Psychiatry</i> , <b>2003</b> , 160, 13-23	11.9	1865
81	Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. <i>Archives of General Psychiatry</i> , <b>2003</b> , 60, 1228-35		337
80	Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. <i>Neuropsychopharmacology</i> , <b>2003</b> , 28, 1433-9	8.7	48
79	The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. <i>Psychopharmacology</i> , <b>2003</b> , 165, 166-71	4.7	51
78	Effect of antipsychotics on cortical inhibition using transcranial magnetic stimulation. <i>Psychopharmacology</i> , <b>2003</b> , 170, 255-262	4.7	36
77	Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: a replication study. <i>Pharmacology Biochemistry and Behavior</i> , <b>2003</b> , 74, 425-32	3.9	67
76	Anesthetics inhibit high-affinity states of dopamine D2 and other G-linked receptors. <i>Synapse</i> , <b>2003</b> , 50, 35-40	2.4	66
75	Amoxapine shows atypical antipsychotic effects in patients with schizophrenia: results from a prospective open-label study. <i>Schizophrenia Research</i> , <b>2003</b> , 59, 35-9	3.6	15
74	Apathy in schizophrenia: clinical correlates and association with functional outcome. <i>Schizophrenia Research</i> , <b>2003</b> , 63, 79-88	3.6	91
73	Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. <i>Schizophrenia Research</i> , <b>2003</b> , 64, 103-14	3.6	84
72	Half a century of antipsychotics and still a central role for dopamine D2 receptors. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2003</b> , 27, 1081-90	5.5	445
71	Direct activation of the ventral striatum in anticipation of aversive stimuli. <i>Neuron</i> , <b>2003</b> , 40, 1251-7	13.9	372

70	Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects. <i>Journal of Psychiatry and Neuroscience</i> , <b>2003</b> , 28, 293-9	4.5	18
69	From Dopamine to Psychosis: A Computational Approach. <i>Lecture Notes in Computer Science</i> , <b>2003</b> , 1115-1121	11.1	11
68	Clozapine can induce high dopamine D(2) receptor occupancy in vivo. <i>Psychopharmacology</i> , <b>2002</b> , 160, 107-12	4.7	17
67	Amphetamine-sensitized animals show a marked increase in dopamine D2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges. <i>Synapse</i> , <b>2002</b> , 46, 235-9	2.4	68
66	NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2) receptors-implications for models of schizophrenia. <i>Molecular Psychiatry</i> , <b>2002</b> , 7, 837-44	15.1	360
65	Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation. <i>Archives of General Psychiatry</i> , <b>2002</b> , 59, 347-54		232
64	Review: amisulpride is effective and safe for schizophrenia. <i>Evidence-Based Mental Health</i> , <b>2002</b> , 5, 85	11.1	
63	Elevation of prolactin levels by atypical antipsychotics. <i>American Journal of Psychiatry</i> , <b>2002</b> , 159, 133-5	11.9	174
62	The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2002</b> , 302, 1129-34	4.7	135
61	Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action. <i>NeuroReport</i> , <b>2002</b> , 13, 831-5	1.7	26
60	Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. <i>Archives of General Psychiatry</i> , <b>2002</b> , 59, 514-20		115
59	Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. <i>American Journal of Psychiatry</i> , <b>2001</b> , 158, 311-4	11.9	84
58	Drug-induced receptor occupancy: substantial differences in measurements made in vivo vs ex vivo. <i>Psychopharmacology</i> , <b>2001</b> , 157, 168-71	4.7	27
57	Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. <i>Neuropsychopharmacology</i> , <b>2001</b> , 25, 633-41	8.7	187
56	Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. <i>American Journal of Psychiatry</i> , <b>2001</b> , 158, 360-9	11.9	990
55	Inverse relationship between serotonin 5-HT(1A) receptor binding and anxiety: a [(11C)WAY-100635 PET investigation in healthy volunteers. <i>American Journal of Psychiatry</i> , <b>2001</b> , 158, 1326-8	11.9	120
54	The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18F]setoperone PET imaging study. <i>American Journal of Psychiatry</i> , <b>2001</b> , 158, 78-85	11.9	189
53	Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D2 receptor. <i>Biological Psychiatry</i> , <b>2001</b> , 49, 954-7	7.9	44

52	Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. <i>Biological Psychiatry</i> , <b>2001</b> , 50, 873-83	7.9	294
51	Comment on [Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D2 receptor]Reply. <i>Biological Psychiatry</i> , <b>2001</b> , 50, 555-556	7.9	3
50	Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies. <i>CNS Drugs</i> , <b>2001</b> , 15, 671-8	6.7	60
49	Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. <i>Annual Review of Medicine</i> , <b>2001</b> , 52, 503-17	17.4	262
48	The Role of Neuroimaging in Development of and Treatment With Antipsychotics. <i>Journal of Pharmacy Practice</i> , <b>2001</b> , 14, 332-340	1.3	
47	Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis. <i>Clinical Neuropharmacology</i> , <b>2001</b> , 24, 242-4	1.4	15
46	Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench. <i>Canadian Journal of Psychiatry</i> , <b>2000</b> , 45, 241-6	4.8	62
45	Dopamine D(2) receptor blockade by haloperidol. (3)H-raclopride reveals much higher occupancy than EEDQ. <i>Neuropsychopharmacology</i> , <b>2000</b> , 23, 595-8	8.7	17
44	Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. <i>Psychopharmacology</i> , <b>2000</b> , 150, 422-9	4.7	137
43	Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. <i>Psychopharmacology</i> , <b>2000</b> , 152, 174-80	4.7	215
42	Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. <i>American Journal of Psychiatry</i> , <b>2000</b> , 157, 514-20	11.9	844
41	Schizophrenia: more dopamine, more D2 receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2000</b> , 97, 7673-5	11.5	205
40	The effect of divided attention on encoding and retrieval in episodic memory revealed by positron emission tomography. <i>Journal of Cognitive Neuroscience</i> , <b>2000</b> , 12, 267-80	3.1	106
39	The effects of divided attention on encoding- and retrieval-related brain activity: A PET study of younger and older adults. <i>Journal of Cognitive Neuroscience</i> , <b>2000</b> , 12, 775-92	3.1	179
38	Antipsychoticlike effects of amoxapine, without catalepsy, using the prepulse inhibition of the acoustic startle reflex test in rats. <i>Biological Psychiatry</i> , <b>2000</b> , 47, 670-6	7.9	11
37	A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT(2A) receptor changes in schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , <b>2000</b> , 99, 123-35	2.9	39
36	A positron emission tomography study of silent and oral single word reading in stuttering and nonstuttering adults. <i>Journal of Speech, Language, and Hearing Research</i> , <b>2000</b> , 43, 1038-53	2.8	129
35	Receptor Occupancy by Antipsychotics [Concepts and Findings. <i>Handbooks of Pharmacology and Toxicology</i> , <b>2000</b> , 163-176		6



34	Relationship between central and peripheral serotonin 5-HT <sub>2A</sub> receptors: a positron emission tomography study in healthy individuals. <i>Neuroscience Letters</i> , <b>1999</b> , 261, 139-42	3.3	15
33	Is amoxapine an atypical antipsychotic? Positron-emission tomography investigation of its dopamine <sub>2</sub> and serotonin <sub>2</sub> occupancy. <i>Biological Psychiatry</i> , <b>1999</b> , 45, 1217-20	7.9	63
32	Serotonin 5-HT <sub>2</sub> receptors in schizophrenia: a PET study using [ <sup>18</sup> F]setoperone in neuroleptic-naive patients and normal subjects. <i>American Journal of Psychiatry</i> , <b>1999</b> , 156, 72-8	11.9	92
31	Mapping neural interactivity onto regional activity: an analysis of semantic processing and response mode interactions. <i>NeuroImage</i> , <b>1998</b> , 7, 244-54	7.9	27
30	Task-independent effect of time on rCBF. <i>NeuroImage</i> , <b>1998</b> , 7, 314-25	7.9	32
29	Neuroanatomical correlates of human reasoning. <i>Journal of Cognitive Neuroscience</i> , <b>1998</b> , 10, 293-302	3.1	255
28	Cerebral gray matter volume deficits in first episode psychosis. <i>Archives of General Psychiatry</i> , <b>1998</b> , 55, 540-6		107
27	5-HT <sub>2</sub> and D <sub>2</sub> receptor occupancy of olanzapine in schizophrenia: a PET investigation. <i>American Journal of Psychiatry</i> , <b>1998</b> , 155, 921-8	11.9	308
26	Functional network differences in schizophrenia: a rCBF study of semantic processing. <i>NeuroReport</i> , <b>1998</b> , 9, 1697-700	1.7	45
25	Pharmacotherapy of first-episode schizophrenia. <i>British Journal of Psychiatry</i> , <b>1998</b> , 172, 66-70	5.4	53
24	New insights into schizophrenia from neuroimaging. <i>Current Opinion in Psychiatry</i> , <b>1998</b> , 11, 33-37	4.9	4
23	The relationship between risperidone plasma levels and dopamine D <sub>2</sub> occupancy: a positron emission tomographic study. <i>Journal of Clinical Psychopharmacology</i> , <b>1998</b> , 18, 82-3	1.7	19
22	PET evidence that loxapine is an equipotent blocker of 5-HT <sub>2</sub> and D <sub>2</sub> receptors: implications for the therapeutics of schizophrenia. <i>American Journal of Psychiatry</i> , <b>1997</b> , 154, 1525-9	11.9	83
21	Reliability of a simple non-invasive method for the evaluation of 5-HT <sub>2</sub> receptors using [ <sup>18</sup> F]-setoperone PET imaging. <i>Nuclear Medicine Communications</i> , <b>1997</b> , 18, 395-9	1.6	29
20	The seats of reason? An imaging study of deductive and inductive reasoning. <i>NeuroReport</i> , <b>1997</b> , 8, 1305-10	1.7	255
19	Cognitive subtractions may not add up: the interaction between semantic processing and response mode. <i>NeuroImage</i> , <b>1997</b> , 5, 229-39	7.9	83
18	Functional Neuroanatomy of Recall and Recognition: A PET Study of Episodic Memory. <i>Journal of Cognitive Neuroscience</i> , <b>1997</b> , 9, 254-65	3.1	181
17	Age-related differences in neural activity during memory encoding and retrieval: a positron emission tomography study. <i>Journal of Neuroscience</i> , <b>1997</b> , 17, 391-400	6.6	607

16	The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. <i>Psychopharmacology</i> , <b>1997</b> , 131, 148-52	4.7	101
15	Neuromodulation of frontal and temporal cortex by intravenous d-fenfluramine: an [15O]H2O PET study in humans. <i>Neuroscience Letters</i> , <b>1996</b> , 207, 25-8	3.3	33
14	The neural correlates of intentional learning of verbal materials: a PET study in humans. <i>Cognitive Brain Research</i> , <b>1996</b> , 4, 243-9		132
13	Effects of self-generated sad mood on regional cerebral activity: a PET study in normal subjects. <i>Depression</i> , <b>1996</b> , 4, 81-8		53
12	The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. <i>Life Sciences</i> , <b>1995</b> , 57, PL103-7	6.8	150
11	Dissociation of pathways for object and spatial vision: a PET study in humans. <i>NeuroReport</i> , <b>1995</b> , 6, 1865-8	5.8	111
10	Functional role of the prefrontal cortex in retrieval of memories: a PET study. <i>NeuroReport</i> , <b>1995</b> , 6, 1880-4	4	276
9	Modulation of cortical neuronal activity by a serotonergic agent: a PET study in humans. <i>Brain Research</i> , <b>1994</b> , 646, 292-4	3.7	40
8	Activation of specific cortical regions by apomorphine: an [15O]H2O PET study in humans. <i>Neuroscience Letters</i> , <b>1994</b> , 176, 21-4	3.3	31
7	The role of the left prefrontal cortex in verbal processing: semantic processing or willed action?. <i>NeuroReport</i> , <b>1994</b> , 5, 2193-6	1.7	205
6	Electroconvulsive shock increases tyrosine hydroxylase and neuropeptide Y gene expression in the locus coeruleus. <i>Molecular Brain Research</i> , <b>1993</b> , 18, 121-6		18
5	Role of the dopaminergic system in depression. <i>Biological Psychiatry</i> , <b>1992</b> , 32, 1-17	7.9	277
4	Use of random-sequence riboflavin as a marker of medication compliance in chronic schizophrenics. <i>Schizophrenia Research</i> , <b>1991</b> , 6, 49-53	3.6	22
3	Imaging of brain structure and function: relevance to psychiatric disorders68-79		
2	Functional Neuroimaging in Psychiatry167-193		
1	The Pharmacology of Typical and Atypical Antipsychotics55-71		2